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Cost-Effective Asthma Treatments
for Uninsured or Underinsured
Pediatric Patients
Karlen E. Luthy, DNP, FNP, Emilianne Dougall, MS, FNP,
and Renea L. Beckstrand, PhD, CCRN
ABSTRACT
Nurse practitioners should constantly compare a medication’s potential effect
with its associated cost, thus identifying the most cost-effective treatment plan.
Such an approach is warranted for both pediatric and adult patients. Prescribing
medications for children who are uninsured or underinsured can be especially
challenging, particularly for those patients diagnosed with a chronic health condition requiring routine treatment and follow-up. Asthma can be such a chronic
illness for which the cost associated with treatment may become a barrier to
compliance with the treatment plan. Cost-effective treatment options for asthma
in the pediatric patient are presented.
Keywords: asthma, cost-effective, medication, pediatric, underinsured, uninsured
© 2012 American College of Nurse Practitioners
Figures 1 and 2 are available online at www.npjournal.org.

I

n 2010, 46.2 million Americans were living in
poverty and 49.9 million did not have health insurance,1 an increase of 900,000 since 2009. In addition, the percentage of Americans covered by private
health insurance and employment-based health insurance
has been decreasing since 2008.2 Regrettably, the decreasing number of insured employees and rising costs of
insurance rates have directly and negatively influenced the
health of children who, consequently, are also uninsured.3
In 2010, 9.8% of children under the age of 18 in the
United States were identified as uninsured, accounting
for 7.3 million children.1 Despite recent expansions of
Medicaid and the Children’s Health Insurance Program
(CHIP), the number of uninsured US children has
improved by only 1.7% since 2006.4 Many of these uninsured children live in families whose income is below the
federal poverty line and are 3 times less likely to visit
health care providers.4 Additionally, all underinsured
pediatric patients are less likely to have their prescriptions
filled than are children with adequate private insurance.5
Treating asthma patients under 18 years old costs
an estimated $3.2 billion per year.6 Children from
poor and low-income neighborhoods have a higher
636
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prevalence of asthma7 and are 3 times more likely to
experience acute exacerbations, necessitating more frequent emergency department (ED) visits and hospitalizations.8 Consequently, health care providers must be
able to offer uninsured or underinsured families costeffective treatment plans.9 The purpose of this article is
to review treatment plans for asthma management in
pediatric patients and compare the cost and effectiveness of asthma medications.
METHODS
Multiple searches of electronic databases were conducted
to identify studies related to the treatment of pediatric
patients with asthma. Electronic databases included
CINAHL, Medline, EBSCO, Clinical Pharmacology,
Epocrates, Micromedex, UptoDate, and the Cochrane
Library. An Internet search of government and professional organization Web sites were reviewed.
Inclusion criteria were English articles published in
the past 5 years. Articles in which advanced treatment
plans for asthma management or asthma medications not
appropriate for use in pediatric patients were excluded.
Search terms included asthma, cost, compliance,
Volume 8, Issue 8, September 2012

treatment, medication, guidelines, cost-related nonadherence, uninsured, pediatric, and children.
REVIEW OF ASTHMA-RELATED COSTS
Asthma is a chronic respiratory disease where inflammation and subsequent narrowing of small airways cause
shortness of breath, coughing, wheezing, and chest pain.
Episodes of impaired breathing can be caused by various
triggers.10 According to the Centers for Disease Control
and Prevention,11 an estimated 7.1 million children have
asthma, making it the most common pediatric chronic
illness in America.6,12 Health care expenditures for children with asthma are 1.5 times greater than children
without asthma.13 In fact 75% of asthma-related costs are
related to ED visits.14 The economic burden of asthma
includes direct costs, such as prescription costs and
provider visits, or indirect costs, such as absenteeism
from school.14,15

sulted at step 3 management for patients 5–11 years old,
although an asthma specialist is required at step 4 for all
patients 5–11 years old16 (Figures 1 and 2).
Step 1
SABAs are the first line of therapy for children with
intermittent asthma and include albuterol and levalubterol as needed. Referred to as rescue inhalers, SABAs
have a quick onset and are used for acute exacerbations
of asthma symptoms. As preventive medications, SABAs
can also be administered 10 minutes before activities that
commonly trigger symptoms, such as exercise.18 Patients
using SABA inhalers more than 2 times per week for at
least 1 month or who are not adequately controlled
should be advanced from step 1 to step 2 treatments as
outlined in the National Asthma Prevention Program
guidelines16 (Figures 1 and 2).

Step 2
REVIEW OF ASTHMA MANAGEMENT IN THE PEDIATRIC
Inhaled corticosteroids (ICSs) are recommended for
PATIENT
long-term asthma control in pediatric patients with perThe National Heart, Lung, and Blood Institute16
sistent asthma that is classified by symptom frequency,
(NHLBI) outlines a stepwise pharmacological treatment
excessive SABA use, impairment of normal activity, limiplan of adjusting medication for children 0–11 years old
tations in normal activity, nocturnal awakenings more
with asthma until their sympthan once per week, and the use
toms are controlled (Figures 1
of oral glucocorticoids more
and 2). Before treatment, it is
than twice per year.16 The preimportant to assess the severity
ferred first-line therapy in this
...an
estimated
of a child’s asthma by collectstepwise treatment category is to
7.1 million children
ing a complete history or
add a low-dose ICS to the
spirometry testing results.
patient’s SABA therapy (Figures
have asthma,
Clinicians should then classify
1 and 2), such as beclomethamaking it the most common
the severity of a patient’s
sone, budesonide, fluticasone, or
pediatric
chronic
illness
asthma symptoms while conmometasone, although the
in America.
sidering both current impairchoice of ICS depends on the
ment and future risk.17 Nurse
child’s age and the medication
practitioners (NPs) must also
delivery mode (nebulizer versus
review symptoms such as
inhaler). The addition of ICS
wheezing, use of short-acting beta agonists (SABAs), and
medications prevents lung function loss, improves quality
interference with daily activities.
of life, and reduces risk of severe exacerbations18 for the
NPs can safely manage pediatric asthma patients for
patient with persistent asthma, consequently lowering the
16
step 1 treatments. If patients 0–4 years old are not well
overall cost of asthma treatment.
controlled in step 1, NPs may consider referring to a speThere are a few alternative treatment options to ICS
cialist for step 2 management, although this is not
for patients requiring step 2 asthma therapy, although the
required.16 However, the NHLBI does recommend an
treatment regimen is age dependent. Patients 0–4 years
asthma specialist for step 3 management or higher for all
old are candidates for a leukotriene receptor antagonist
patients 4 years and younger.16 A specialist may be con(LTRA) (montelukast) in lieu of ICS, but in addition
www.npjournal.org
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to continued use of SABAs (Figure 1). For patients
5–11 years old, the practitioner may consider prescribing
theophylline or LTRA (montelukast or zafirlukast) as an
alternative to ICS therapy but in addition to SABAs17
(Figure 2).
While still listed as an alternative to ICS therapy, mast
cell stabilizers (cromolyn) are no longer available in the
US and so were not included for review. Likewise, theophylline is rarely used because of the potential for adverse
side effects and drug interactions and was not included
for review.
Step 3
For children requiring step 3 asthma management, treatment includes an SABA plus a medium-dose ICS
(Figures 1 and 2). A medium-dose ICS is obtained by
increasing the dosages of low-dose inhalers as recommended for the patient’s age. If the practitioner wishes to
avoid the medium-dose ICS, he or she may substitute a
low-dose ICS plus a long-acting beta agonist (LABA) or
LTRA.16 Budesonide is currently the only approved ICS
for patients age 0–4 years and is available as a nebulized
treatment.19 However, for children 5–11 years old,
medium-dose ICS inhalers can be prescribed as part of
a step 3 treatment plan, as long as the child can use an
inhaler.16 Although an option in step 3 treatment,
theophylline was not included for review because of
its potential for adverse side effects.
COMPARISON OF EFFICACY AND COST
SABA
SABAs are safe for children of all ages and can be dispensed as a nebulized treatment or hydrofluroalkane
(HFA) inhaler. There is no significant difference between
the SABA medications albuterol and levalbuterol20 in
efficacy, safety, or prevalence of adverse side effects.21
Therefore, selection of SABAs should be made after
considering medication cost.
The approximate cost of nebulized albuterol is
$43.99/box of the 0.63 mg/3 mL dose or $53.82/box of
the 1.25 mg/3 mL dose. The least expensive dosing
option (0.083 mg/3 mL) can be purchased for about
$18.99/box. Comparably, levalbuterol is more than twice
as expensive as albuterol at about $132.87/box of the
0.31 mg/3 mL dose, $148.23/box of the 0.63 mg/3 mL
dose, or $147.99/box of the 1.25 mg/3 mL dose 22
(Tables 1 and 2).
638
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Albuterol and levalbuterol are also available as an
HFA inhaler. When administered via inhaler, albuterol
is available as Proair (TevaRespiratory, Horsham, PA)
at an approximate cost of $44.99/inhaler, Ventolin
(GlaxoSmithKline, Middlesex, United Kingdom) at
about $45.99/inhaler, or Proventil (Merck & Co., Inc.,
Kenilworth, NJ) at about $55.99/inhaler. Somewhat
comparable in cost, levalbuterol is available as Xopenex
(Sunovion Pharmaceuticals Inc., Marlborough, MA) for
about $59.99/inhaler.22
Inhaled Corticosteroids
ICSs are the most potent asthma treatment available,17
thus reducing bronchial hyperresponsiveness that, in turn,
helps maintain and enhance lung function long term.23
Because of potentially negative side effects, steroid use in
the pediatric patient usually causes concern, although
ICSs deliver steroids directly to the airways, causing fewer
systemic side effects.17,24 In children, daily use of ICSs is
the most effective controller of persistent asthma symptoms and acute exacerbations.24-25 However, ICSs are
often underprescribed, despite the proven benefits in
reducing asthma exacerbations.
There are currently 4 ICSs on the market for use in
pediatric patients age 11 years and younger; however, the
cost of treatment significantly increases when using an
ICS in comparison to SABA alone. When selecting the
most cost-effective and appropriate ICS for a child, consider age, ability of the patient to effectively use an
inhaler, and compliance issues associated with frequency
of dosing.
Beclomethasone (BDP) is prescribed starting at 1 puff
twice per day for patients 5 years and older. BDP metabolizes into beclomethasone monopropriate (BMP) in the
lung tissue and extrapulmonary tissue,23 increasing local
side effects that must be considered when prescribing to
young children who have difficulty synchronizing inhaling with dispensing the medication. BDP is as effective
as fluticasone (FP),26 another ICS, although BDP usually
causes less adrenal suppression.23 The cost of BDP is
about $113.99/inhaler22 (Table 2).
Budesonide (BUD) is the only ICS appropriate for
patients as young as 1 year and can be administered via
nebulizer or inhaler. Moreover, BUD has a low incidence
of oropharyngeal side effects and is the least potent, systemically, compared with other ICSs.24 The cost of BUD
is approximately $121.99/inhaler. For children who
Volume 8, Issue 8, September 2012

Table 1. Cost Comparison of Asthma Medications for Children 0–4 Years Old
Step 1:
SABA
Albuterol
HFA
$44.99/inhaler

Step 2 Preferred:
SABA 1 Low-dose ICS
SABA ⫹ Budesonide

Nebulized
Budesonide HFA
$18.99/box
$121.99/inhaler
(0.083 mg/
3 mL)
or
$43.99/box
(0.63 mg/3 mL)
or
$53.82/box
(1.25 mg/3 mL)

Budesonide Nebulized
$205.99/box
(.25 mg/2 mL)

Step 3
Consultation
Recommended

Step 2 Alternative:

Levalbuterol

SABA ⫹ LTRA (Montelukast)
HFA
$59.99/inhaler

Nebulized
Montelukast granules
$132.87/box
$169.05/box 4 mg
(0.31 mg/3 mL)
or
$148.23/box
(0.63 mg/3 mL)
or
$147.99/box
(1.25 mg/3 mL)

Montelukast chewable
$166.91/bottle of 4 mg

SABA ⫽ short-acting beta agonist; ICS ⫽ inhaled corticosteroids; HFA ⫽ hydroﬂuroalkane; LTRA ⫽ leukotriene receptor antagonist.
Step 1 Recommendation: Albuterol is the most cost-efﬁcient option in both HFA and nebulized solution.
Step 2 Recommendation: SABA ⫹ budesonide is the preferred therapy. When age appropriate, budesonide HFA is the most cost-efﬁcient option

cannot effectively use an inhaler, BUD is also available as
a nebulized solution, costing about $205.99/box for
0.25 mg/2 mL doses22 (Tables 1 and 2).
FP has been established as a safe and effective medication to treat persistent asthma symptoms. With a low
occurrence of both systemic and oral side effects, FP is
often prescribed with twice daily dosing and has the
greatest variety of dosing increments of any ICS. This
variety may be advantageous for practitioners adjusting
medication dosages for pediatric patients to achieve adequate symptom management, at the lowest possible prescribed dose. When compared with some of the newer
HFA ICSs, FP has similar outcomes.23 FP compared with
BDP and BUD was equally effective in reducing exacerbation and appears to be more effective in improving
morning peak flows.25 Compared with BUD or BDP, FP
can be prescribed at half the dose without significant
clinical differences.25 For a single inhaler, FP costs about
$119.9922 (Table 2).
www.npjournal.org

Mometasone furoate (MF) is the only ICS with
once daily dosing. When inhaled, MF has less than 1%
bioavailability and no absorption occurs through the
digestive tract.23 Furthermore, MF administered via dry
powder inhaler is well tolerated and has similar effects
compared to BDP. Comparatively, MF is equally as
effective as FP and more efficacious than BDP and
BUD.23 MF costs approximately $130.99/inhaler22
(Table 2).
OTHER ALTERNATIVE THERAPIES TO ICS
Montelukast, an LTRA, is approved for patients 1 year and
older. When compared with placebo, montelukast reduced
asthma symptoms, but when compared with ICS or systemic steroids, it was not as effective in reducing seasonal
asthma symptoms or preventing rescue medication use or
unanticipated health care visits.21 Although about a quarter
of patients will have a greater benefit using montelukast,
low-dose ICS appears to be more effective.27 Available in
The Journal for Nurse Practitioners - JNP
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Table 2. Cost Comparison of Asthma Medications for Children 5–11 Years Old
Step 1:

Step 2 Preferred:
SABA ⫹ Low-dose ICS

SABA
Albuterol
HFA

Step 3:

Beclomethasone
$113.99/inhaler

SABA ⫹ Medium-dose ICS
Beclomethasone
$113.99/inhaler

Nebulized

Budesonide
$44.99/inhaler $18.99/box (0.083 $121.99/inhaler
mg/3 mL)
Fluticasone
or
$119.99/inhaler
$43.99/box
(0.63 mg/3 mL) Mometasone
$130.99/inhaler
or

Budesonide
$121.99/inhaler
Fluticasone
$119.99/inhaler
Mometasone
$130.99/inhaler

$53.82/box
(1.25 mg/3 mL)
Step 2 Alternative:
SABA ⫹ LTRA

Levalbuterol
HFA
Nebulized
$59.99/inhaler $132.87/box
(0.31 mg/3 mL)
or
$148.23/box
(0.63 mg/3 mL)
or
$147.99/box
(1.25 mg/3 mL)

LTRA: Montelukast
$169.05/box
4-mg granules
or
$166.91/bottle
4-mg chewable

LTRA: Zaﬁrlukast
$89.99/60 tablets
10-mg chewable

SABA ⫹ Low-dose ICS ⫹ LTRA
LTRA: Montelukast
$169.05/box 4-mg granules
or
$166.91/bottle 4-mg chewable
or
LTRA: Zaﬁrlukast
$89.99/60 tablets 10-mg chewable

SABA ⫹ Low dose ICS ⫹ LABA
LABA:
Formoterol
$175.99/inhaler

LABA:
Salmeterol
$180.99/inhaler

SABA ⫽ short-acting beta agonist; ICS ⫽ inhaled corticosteroids; HFA ⫽ hydroﬂuroalkane; LTRA ⫽ leukotriene receptor antagonist; LABA ⫽
long-acting beta agonist.
Step 1 Recommendation: Albuterol is the most cost-efﬁcient option in both HFA and nebulized solution.
Step 2 Recommendation: Low-dose beclomethasone is the most cost-efﬁcient option as adjunct treatment to SABA.
Step 3 Recommendation: Medium-dose beclomethasone is the most cost-efﬁcient option as adjunct treatment to SABA.

granules, tablets, or chewables, montelukast costs about
$169.05 for 30 packets of the 4 mg granules.22 The chewable tablets are slightly less expensive at a cost of about
$166.91 for 30 of the 4 mg dose22 (Tables 1 and 2).
Another LTRA, zafirlukast, is approved for use in
patients ages 5 years and older, has few side effects, and
can be a good second-line choice in chronic asthma
patients when ICSs are not available or well tolerated.
However, long-term use shows some reduction of efficacy and rebound deterioration when the medication is
stopped.28 It is dosed as 10-mg tablets twice daily.19 For
60 of the 10-mg tablets, zafirlukast costs around $89.9922
(Table 2).
640
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Salmeterol and formoterol, LABAs, are used in
combination with ICS. Because of risk of near fatal
asthma attacks, the Food and Drug Administration
(FDA) has advised against the use of LABA in treating
mild asthma patients.29 Despite FDA warning, once
daily dosing of low dose FP with LABA is as effective
as FP dosed twice daily and more effective than
LTRA.30 Adding an LABA is more effective for most
patients than adding an LTRA or increasing to a
medium dose inhaler.27 Combined ICS with LABA
(salmeterol/fluticasone, formoterol/budesonide, formoterol/mometasone) are approved only for children
12 years and older.19 Formoterol costs $175.99/
Volume 8, Issue 8, September 2012

inhaler. Salmeterol is slightly more expensive, costing
about $180.99/inhaler22 (Table 2).
IMPLICATIONS FOR PRACTICE
With so much at stake for the well-being of a pediatric
patient, NPs can be influential in improving asthma outcomes through appropriate prescribing during the management of treatment plans. Optimum asthma control
reduces medical costs overall and improves quality of
life.14 In order to keep costs at a minimum for patients,
there must be a balance between affordability of medications and avoidance of exacerbations that lead to
increased costs associated with hospitalization.
Most commonly, nonadherence to an asthma treatment regimen is a result of the complexity of treatment
plans, low patient perception of need for treatment, dosing frequency, cost, and negative side effects.12 The progression from step 1 to step 2 in a treatment plan
includes increasing medication administration frequency
from an as-needed basis to 1–4 times daily. As a result,
costs associated with asthma treatment increase. Given
the monthly cost incurred from ICS, many patients often
forego this medication and continue to refill SABAs
despite the need for longer-acting medications.15
Generally speaking, patients who use SABAs alone are
more likely to need ED services for acute asthma exacerbations, thus incurring a greater overall expenditure that
could be otherwise reduced or prevented.
Practitioners need to encourage open-ended conversations with patients and parents related to compliance.
As such, it is also helpful to inform patients and parents
of prescription costs before their arrival at the pharmacy.12 To assist patients in purchasing more expensive
medications, NPs can facilitate finding online coupons,
prescription assistance programs, and generic options
when available.
STEP 1 RECOMMENDATIONS
Nebulized solutions, such as albuterol and levalbuterol, are
equally as effective for patients with intermittent asthma. If
there is, indeed, no significant difference in efficacy, safety,
or adverse side effects,21 then age should guide the
provider’s decision. Because albuterol nebulized solution is
appropriate for children 0–11 years old, coupled with the
fact that it is also significantly less expensive than levalbuterol, albuterol is the most efficacious option (Table 1).
Both albuterol and levalbuterol are also available in an
www.npjournal.org

inhaler form. However, because there is no significant difference between effectiveness, safety, or side effects of these
medications, as well as the fact that all these inhalers are
appropriate for use in children 4–11 years old, the most
cost-effective choice would be albuterol (Tables 1 and 2).
STEP 2 RECOMMENDATIONS
If asthma symptoms are not controlled with SABAs
alone, the patient is most effectively treated with
step 2 guidelines. Based upon price alone, BDP
($113.99/inhaler) is the most inexpensive option for ICS;
however, FP, which is only slightly more expensive at
$119.99/inhaler, has more available dosing increments.22
As such, FP may be the most cost-effective option for
patients needing dosing adjustments without changing
the medication itself. For patients who have difficulty
following multiple daily dosing, MF ($130.99)22 may be
an option because it is dosed once per day, although
patients will pay slightly more for this medication when
compared to any other ICS option (Table 2).
If low-dose ICS needs to be avoided, adding an alternative adjunct medication such as an LTRA can be considered. The provider can consider prescribing montelukast
for 1–4 year olds and zafirlukast for 5–11 year olds.
STEP 3 RECOMMENDATIONS
For children 0–4 years old, consultation is required if step
2 asthma is not controlled with the use of a low-dose
ICS. For children 5–11 years old, the most cost-effective
option is to increase the ICS to a medium-dose range by
increasing the number of puffs per day, the frequency, or
the dosage. If an increase to a medium-dose ICS is not
effective in controlling asthma symptoms, selecting a
low-dose ICS with an LTRA or LABA may be helpful.
The combined cost of a low-dose ICS with LABA is
roughly equivalent to the cost of a low-dose ICS with an
LTRA (Table 2).
LIMITATIONS
Pediatric-based research comparing new HFA medications
is lacking overall, making it difficult to determine efficacy
among different types of inhalers. Also, research often does
not identify which type of inhaler was studied, which may
affect results. Additionally, because of individualization, differences in severity and response to medications and triggers may affect which medication a child will respond to,
necessitating an individualized plan of care.
The Journal for Nurse Practitioners - JNP
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The cost associated with any medication can change
over time. Therefore, the medication costs listed in this
article may not accurately reflect the costs associated
with medications available in individual communities.
However, we chose a national online pharmacy (drugstore.com) to collect cost-related information. As a
national online pharmacy, drugstore.com is available to
all patients regardless of location. A popular electronic
medical reference program that also uses drugstore.com
for price information, Epocrates, currently has 1.4 million subscribers and is a reference used by approximately 50% of providers.31
Finally, although there may be varied and subtle cost
differences of asthma medications according to individual
location, a review of various retail Web sites revealed that
the least costly medication option was always the least
costly, regardless of pharmacy.
CONCLUSION
NPs play a crucial role in assisting pediatric patients and
families in asthma treatment adherence. NPs must not
only educate patients about the disease but also stay
informed of cost-effective treatment options currently
on the market and explain these costs to families. As NPs
consider the cost associated with asthma treatment, medication compliance may improve, thus decreasing other
asthma-associated costs, such as hospitalizations.
References
1. Denavas WC, Proctor BD, Smith JC. Income, poverty, and health insurance
coverage in the United States: 2010. http://www.census.gov/prod/2011pubs/
p60-239.pdf. Accessed October 26, 2011.
2. Kaiser Commission on Medicaid and the Uninsured. Five basic facts on the
uninsured. Kaiser Family Foundation Web site. http://www.kff.org/uninsured/
upload/7806-04.pdf. Accessed September 9, 2011.
3. Abdullah F, Zhang Y, Larado T, et al. Analysis of 23 million US
hospitalizations: uninsured children have higher all-cause in-hospital
mortality. J Public Health. 2009;32(2):236-244.
4. Johnson TD. Census Bureau: Number of U.S. uninsured rises to 47 million
Americans are uninsured: almost 5 percent increase since 2005. Nations
Health. 2008;37(8). http://www.medscape.com/viewarticle/567737. Accessed
July 21, 2011.
5. Wang NE, Kieran M, Golzari M, Gisondi MA. Characteristics of pediatric
patients at risk for emergency department aftercare. Acad Emerg Med.
2006;13(8):840-847.
6. Centers for Disease Control and Prevention. Healthy youth: Asthma.
http://www.cdc.gov/HealthyYouth/asthma. Accessed July 21, 2011.
7. Akinbami LJ, Moorman JE, Xiang LM. Asthma Prevalence, Health Care Use,
and Mortality: United States, 2005-2009. National Health Statistic Reports
No. 32. Hyattsville, MD: National Center for Health Statistics; 2011.
8. Grant R, Bowen SK, Neidell M, Prinz T, Redlener IE. Health care savings
attributable to integrating guidelines-based asthma care in the pediatric
medical home. J Health Care Poor Underserved. 2010;21(2):88-92.
9. Luthy KE, Peterson NE, Wilkinson J. Cost-efficient treatment options for
uninsured or underinsured patients for five common conditions. J Nurs
Pract. 2008;4(8):577-584.
10. American Academy of Allergy, Asthma & Immunology. Asthma.
http://www.aaaai.org/conditions-and-treatments/asthma.aspx. Accessed
December 7, 2011.
11. Centers for Disease Control and Prevention. FastStats: Asthma.
http://www.cdc.gov/nchs/fastats/asthma.htm. Accessed December 15, 2011.

642

The Journal for Nurse Practitioners - JNP

12. Patel MR, Coffman JM, Tseng C, Clark NM, Cabana MD. Physican
communication regarding cost when prescribing asthma medication to
children. Clin Pediatr. 2009;48(5):493-498.
13. Cloutier MM, Grosse SD, Wakefield DB, Nurmagambetov TA, Brown CM.
The economic impact of an urban asthma management program.
Am J Managed Care. 2009;15(6):345-351.
14. Aguilar GGS, Martinez ZIC, Jurado LS, Colin VH. Asthma exacerbation and
related emergency unit costs. Revista Alergia Mexico. 2006;53(2):64-68.
15. Kleinman NL, Brook RA, Ramachandran S. An employee perspective on
annual employee and dependent costs for pediatric asthma. Ann Allerg
Asthma Im. 2009;103:114-120.
16. National Heart, Lung and Blood Institute. Expert panel report (EPR3):
Guidelines for the diagnosis and management of asthma: Section 4,
managing asthma long term in children 0-4 years of age and 5-11 years
of age. http://www.nhlbi.nih.gov/guidelines/asthma/ 08_sec4_lt_0-11.pdf.
Accessed December 8, 2011.
17. National Heart, Lung and Blood Institute. Expert panel report (EPR3):
Guidelines for the diagnosis and management of asthma: Section 3,
Component 4: medications. http://www.nhlbi.nih.gov/guidelines/
asthma/07_sec3_comp4.pdf. Accessed December 8, 2011.
18. Fanta CH, Fletcher SW, Wood RA, Bochner BS, Hollingsworth H. An
overview of asthma management. http://www.uptodate.com/contents/
an-overview-of-asthma-management. Accessed July 5, 2012.
19. Drug lookup. Epocrates Online Web site. https://online.epocrates.com/home.
Accessed December 8, 2011.
20. Crader M, Borkowski J. Nebulized albuterol versus levalbuterol in pediatric
and adult patients: a review. Formulary. 2009;44(4):108-110.
21. Scarfone RJ, Wood RA, Redding G, TePas E. Acute asthma exacerbations
in children: outpatient management. http://www.uptodate.com/contents/
acute-asthma-exacerbations-in-children-outpatient-management?source⫽
search_result&search⫽Acute⫹asthma⫹exacerbations⫹in⫹children%3A⫹
outpatient&selectedTitle⫽1%7E150. Accessed July 18, 2011.
22. Prescription price checker. Drugstore.com Web site.
http://www.drugstore.com. Accessed December 8, 2011.
23. Abdullah AK, Khan S. Evidence-based selection of inhaled corticosteroids
for treatment of chronic asthma. J Asthma. 2007;44(1):1-12.
24. Gulliver T, Morton R, Eid N. Inhaled corticosteroids in children with asthma:
pharmacological determinants of safety and efficacy and other clinical
considerations. Pediatric Drugs. 2007;9(3):185-194.
25. Adams NP, Lasserson TJ, Cates CJ, Jones P. Cochrane Database of
Systematic Reviews. http://onlinelibrary.wiley.com/doi/10.1002/
14651858.CD002310.pub4/full. Accessed August 1, 2011.
26. Lasserson TJ, Cates CJ, Lasserson EH, White J. Cochrane Database of
Systematic Reviews. http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD005309.pub3/full. Published February 17, 2010. Accessed June 12, 2011.
27. Jartti T. Inhaled corticosteroids or montelukast as the preferred primary longterm treatment for pediatric asthma? Eur J Pediatr. 2007;167(7):731-736.
28. Reid DW, Misso NL, Aggarwal S, Thompson PJ, Johns DP, Walters EH.
Tolerance and rebound with zafirlukast in patients with persistent asthma.
J Negat Results Biomed (online). 2008;7(3).
29. Lemanske RF, Bochner BS, Hollingsworth H. Beta-agonists in asthma:
controversy regarding chronic use. http://www.uptodate.com/contents/
beta-agonists-in-asthma-controversy-regarding-chronic-use. Accessed
Setember 9, 2011.
30. Peters SP, Anthonisen N, Castro M, et al, American Lung Association
Asthma Clinical Research Centers. Randomized comparison of strategies
for reducing treatment in mild persistent asthma. New Engl J Med.
2007;356(20):2027-2039.
31. Who we are. When decisions need to be made. http://www.epocrates.com/
who. Accessed March 7, 2012.

Karlen E. Luthy, DNP, FNP, is an assistant professor at
Brigham Young University in Provo, UT, and can be reached at
Beth_luthy@byu.edu. Emilianne Dougall, MS, FNP, is a
recent graduate of the university and Renea L. Beckstrand, RN,
PhD, CCRN, CNE, is an associate professor at the university.
In compliance with national ethical guidelines, the authors report
no relationships with business or industry that would pose a
conflict of interest.
1555-4155/121/$ see front matter
© 2012 American College of Nurse Practitioners
http://dx.doi.org/10.1016/j.nurpra.2012.03.002

Volume 8, Issue 8, September 2012

